KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

School of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India ...

One pharmacist drew attention to a massive pricing disparity on a key cancer drug, and that disparity may help to explain why ...

Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...

Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development ------ John Adams, PhD Appointed Chief Scientific ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

Out-of-pocket costs like deductibles and copays deter people with cancer from complying with treatment.This creates a ...

After hours: February 21 at 7:41:23 PM EST Loading Chart for BLRX ...

Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.